Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry

May 6, 2023

https://www.globenewswire.com/news-release/2023/05/06/2662911/0/en/Sight-Sciences-Announces-12-month-Results-from-the-First-Minimally-Invasive-Glaucoma-Surgery-MIGS-Comparative-Analysis-of-Real-World-Data-RWD-from-the-American-Academy-of-Ophthalmo.html

MENLO PARK, Calif., May 06, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq:SGHT), an eyecare technology company focused on developing and commercializing innovative technology that enables procedures intended to improve patients’ lives, today announced the results from a 12-month retrospective sub-analysis of IOP-lowering medication use following the three most commonly performed, FDA approved (or cleared) MIGS procedures in patients with mild stage glaucoma. Analysis included 16,789 patients in 4 different cohorts: 1) procedures enabled by OMNI® Surgical System technology in combination with cataract 2) iStent Inject® in combination with cataract 3) Hydrus® in combination with cataract or 4) cataract surgery alone.

Read more at globenewswire.com

Related news for (SGHT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.